|
|
Contrary to studies with tacrine, the presence of the apolipoprotein E e4 allele did not predict donepezil treatment failure. Most common adverse events related to donepazil therapy were nausea (5 patients), diarrhea (e patients), and agi tation (3 patients). Serious events possibly related to drug use were seizure, pancreatitis, and syncope (1 patient each). This independent confirmation of data from phase 3 trials suggests that donepezil therapy modestly improves cognition in patients with Alzheimer disease who are encountered in clinical practice. |
|